

HBV in the UK: economic aspects



**J Edmunds¹, R Siddiqui¹, S Hahne², N Gay¹,
A Sutton¹, M Ramsay²**

¹ Modelling & Economics Unit, HPA Centre for Infections

² Immunisation Dept., HPA Centre for Infections

- Review epidemiology
- Universal options
 - Economic model
 - Parameterisation
 - Results & sensitivity analyses
- Alternative options
- Discussion

Review of epidemiology (Hahne et al. 2004)



- Incidence is low in England & Wales

- ~670 laboratory reports / yr
- ~3,800 infections / yr
- ~ 280 chronic carriers / yr



- Most cases occur in risk groups

- Most (~95%) carriers living in UK acquired infection abroad

- ~6,500 new carriers immigrate

- Implications

- Vaccination of risk groups may be more cost-effective
- Universal vaccination will not lead to a significant reduction in resource use




Cohort model

from Fenn et al. 1996, & Anderson, unpublished



- Cohort of individuals followed from birth (either vaccinated or not)

- Susceptible
- Acute infection
- Acute (fulminant) liver failure
- Chronic carrier
- Cirrhosis
- Decompensated cirrhosis
- HCC
- Immune
- Death




- Costs and benefits (life-years lost) compared in two cohorts
- Vaccination occurs in infancy (3 doses) or adolescence (2 doses)
- Males and females treated separately (incidence & progression differs)
- Transmission ignored (benefits underestimated)

Cohort model

epidemiological & demographic parameters



- Incidence taken from Hahne *et al.* (assume stable through time)
- Also used South Asian estimates as part of sensitivity analysis
- Background mortality from ONS
- Most transition probabilities taken from literature
- E.g. Cirrhosis to decomp cirrhosis and HCC from Fattovich *et al.* 1993





Cohort model

epidemiological & demographic parameters



- Little data on key progression (carrier to cirrhosis)
- Estimates of 0.6 – 2.1% per yr
- Progression rates chosen to give ~25% developing HCC over lifetime
- Do not fit observed data on time-course of progression (data from Taiwan and US)
- Estimated transition probabilities by fitting model to (male) data
- Taiwanese (higher) estimates
- US (lower) estimates
- Estimated rates for younger & older adults & when progression rates change




Cohort model

epidemiological & demographic parameters



- Estimated lower progression rates for females
- Based on difference in HBV mortality (HCC & cirrhosis) observed in The Gambia
- Rates 5 times lower than for men



Cohort model other assumptions (base-case)



- Vaccine coverage = 90%
- Both infant and adolescent
- Vaccine efficacy = 90%
- Both infant and adolescent
- Life-long immunity
- Adolescent vaccination given at 12 years of age

- Future costs and health benefits are discounted at 3.5% per annum (as recommended by NICE)

Cohort model cost parameters




- NHS perspective
- Base-case cost per vaccine course
 - Infant = £15 (3 doses @ £5)
 - Adolescent = £15 (2 doses plus £5 administration)
- Treatment costs taken from literature & standard sources
 - often HCV
- Inflated to £2003

Item	Units (per)	Cost (£)	Source
Acute HBV (no transplant)	Episode	1,747	Struve & Giesecke (1993)
Compensated cirrhosis	Year	1,674	Grieve & Roberts (2002)
Decompensated cirrhosis	Year	10,114	Grieve & Roberts (2002)
HCC	Year	9,729	Grieve & Roberts (2002)
Fulminant hepatitis	Episode	4,401	NHS Reference Costs (2003)
Liver transplant	Episode	50,518	Grieve & Roberts (2002)

Base-case results: universal infant vaccination



Estimated number of HBV associated deaths and acute morbidity in cohort with and without universal infant vaccination




~80 % reduction in HBV associated deaths

Base-case results: universal adolescent vaccination



Estimated number of HBV associated deaths and acute morbidity in cohort with and without universal adolescent vaccination



~60 % reduction in HBV associated chronic deaths

Cost-effectiveness

Base-case results



Cost (£) per discounted life year gained of vaccination compared with current strategy

	Infant	Adolescent
Taiwan (high progression)	41,000	30,000
USA (lower progression)	106,000	73,000

Cost-effectiveness

Sensitivity to discount rate




Cost (£) per discounted life year gained of vaccination compared with current strategy. **No discounting of benefits**

	Infant	Adolescent
Taiwan (high progression)	41,000 5,700	30,000 6,400
USA (lower progression)	106,000	73,000

Cost-effectiveness


Sensitivity to cost per course



Cost-effectiveness: Sensitivity to incidence




Cost per life-year gained of infant vaccination compared with current strategy for UK population and South Asians



Cost-effectiveness: Length of immunity



Cost per life-year gained of infant vaccination compared with current strategy for UK population and South Asians



- **Adolescent vaccination less effective, but more cost-effective**
 - As vaccine given closer to age at which risk is highest
 - Assumes costs per course for infant & adolescent are the same
 - At £33 per course (Wallace et al.)
 - cost per LYG ~ £70,000 (base-case, Taiwan)
- **South Asian incidence is higher than overall UK population**
 - More cost-effective to vaccinate South Asians (& other ethnic groups)
 - If 40% of population with higher incidence (assumed = South Asians)
 - Cost per LYG (infant) = 30,000 (Taiwanese progression rates)
 - May be cost-effective to target populations with high ethnic minority population

Alternative (selective strategies)

Prison vaccination (A Sutton)



- IDUs are major risk group for HBV
- More likely to be imprisoned than others
- HBV vaccination is being offered on reception to prisons in England & Wales
 - 3 dose programme (0, 7, 21 days)
- Model developed to assess
 - Coverage expected in IDUs over time
 - Impact on HBV transmission over time

Parameterising the models



- **Characteristics of IDUs**

- UA survey

- **Imprisonment rates**



- Routine data, UA, Prison Survey

- **Vaccine coverage**

- Scenario & routine surveillance

- **Force of infection**


- UA survey




Model results



- Estimated % IDUs vaccinated through prison programme



- Estimated impact on acute HBV



- Low incidence of HBV in the UK
- Vaccination will have little impact on burden of HBV associated chronic disease
- Universal Infant / adolescent vaccination unlikely to be cost-effective
- Vaccination by risk group more likely to be cost effective (perhaps geographically selective?)
- Improving selective programme (e.g. through prisons) has potential to reduce transmission
- Will adversely affect C/E of universal programmes